Michael Orth1, Juliana Bronzova1, Christine Tritsch1, E Ray Dorsey2, Joaquim J Ferreira3, Armin Gemperli4,5. 1. Department of Neurology Ulm University Hospital Ulm Germany. 2. Department of Neurology University of Rochester Medical Center Rochester New York USA. 3. Clinical Pharmacology Unit Instituto de Medicina Molecular Faculty of Medicine University of Lisbon Lisbon Portugal. 4. Department of Health Sciences and Health Policy University of Lucerne Lucerne Switzerland. 5. Swiss Paraplegic Research Nottwil Switzerland.
Abstract
BACKGROUND: In a rare disorder such as Huntington's disease (HD), a global network of clinical trial sites with access to patients speeds up recruitment into clinical trials. The objective was to test the hypothesis that demographics, HTT genotype, clinical spectrum, and progression are similar in HD participants of two large observational HD studies, the European Huntington's Disease Network's European REGISTRY study and the North American COHORT study. METHODS: REGISTRY cross-sectional data were available from a total of 7,384 participants (1,125 [15.2%] premanifest and 6,259 [84.8%] manifest HD). COHORT cross-sectional data from 1,499 participants at 44 study sites were available (175 pre-HD [11.7%], 1,324 manifest HD [88.3%]). Participants were assessed clinically using the Unified Huntington's Disease Rating Scale (UHDRS). Longitudinal data were available for total motor score and cognitive performance in more than 50% of REGISTRY participants and more than 70% of COHORT participants. RESULTS: Demographics, HTT genotypes, phenotype, and progression were similar in the two studies. Patients in Europe were prescribed antidyskinetics more frequently, and antidepressants less frequently, than in North America. In either study, participants on antidyskinetic medication had higher UHDRS total motor scores, worse function assessment scores, and worse cognitive scores than those taking antidepressants or no medication. In contrast, motor, function assessment, and cognitive scores were broadly similar in participants taking antidepressants or no medication. The differences in cognitive performances between languages were small. CONCLUSIONS: Our data suggest that HD patients, and the way they are assessed, are similar across two continents with different cultures and languages.
BACKGROUND: In a rare disorder such as Huntington's disease (HD), a global network of clinical trial sites with access to patients speeds up recruitment into clinical trials. The objective was to test the hypothesis that demographics, HTT genotype, clinical spectrum, and progression are similar in HD participants of two large observational HD studies, the European Huntington's Disease Network's European REGISTRY study and the North American COHORT study. METHODS: REGISTRY cross-sectional data were available from a total of 7,384 participants (1,125 [15.2%] premanifest and 6,259 [84.8%] manifest HD). COHORT cross-sectional data from 1,499 participants at 44 study sites were available (175 pre-HD [11.7%], 1,324 manifest HD [88.3%]). Participants were assessed clinically using the Unified Huntington's Disease Rating Scale (UHDRS). Longitudinal data were available for total motor score and cognitive performance in more than 50% of REGISTRY participants and more than 70% of COHORT participants. RESULTS: Demographics, HTT genotypes, phenotype, and progression were similar in the two studies. Patients in Europe were prescribed antidyskinetics more frequently, and antidepressants less frequently, than in North America. In either study, participants on antidyskinetic medication had higher UHDRS total motor scores, worse function assessment scores, and worse cognitive scores than those taking antidepressants or no medication. In contrast, motor, function assessment, and cognitive scores were broadly similar in participants taking antidepressants or no medication. The differences in cognitive performances between languages were small. CONCLUSIONS: Our data suggest that HD patients, and the way they are assessed, are similar across two continents with different cultures and languages.
Authors: Michael Orth; O J Handley; C Schwenke; S Dunnett; E J Wild; S J Tabrizi; G B Landwehrmeyer Journal: J Neurol Neurosurg Psychiatry Date: 2010-11-19 Impact factor: 10.154
Authors: E Ray Dorsey; Christopher A Beck; Kristin Darwin; Paige Nichols; Alicia F D Brocht; Kevin M Biglan; Ira Shoulson Journal: JAMA Neurol Date: 2013-12 Impact factor: 18.302
Authors: Jane S Paulsen; Jeffrey D Long; Christopher A Ross; Deborah L Harrington; Cheryl J Erwin; Janet K Williams; Holly James Westervelt; Hans J Johnson; Elizabeth H Aylward; Ying Zhang; H Jeremy Bockholt; Roger A Barker Journal: Lancet Neurol Date: 2014-11-03 Impact factor: 44.182
Authors: Helen E Grote; Natalie D Bull; Monique L Howard; Anton van Dellen; Colin Blakemore; Perry F Bartlett; Anthony J Hannan Journal: Eur J Neurosci Date: 2005-10 Impact factor: 3.386
Authors: Sarah J Tabrizi; Rachael I Scahill; Gail Owen; Alexandra Durr; Blair R Leavitt; Raymund A Roos; Beth Borowsky; Bernhard Landwehrmeyer; Chris Frost; Hans Johnson; David Craufurd; Ralf Reilmann; Julie C Stout; Douglas R Langbehn Journal: Lancet Neurol Date: 2013-05-09 Impact factor: 44.182
Authors: Karen Anderson; David Craufurd; Mary C Edmondson; Nathan Goodman; Mark Groves; Erik van Duijn; Daniel P van Kammen; Lavonne Goodman Journal: PLoS Curr Date: 2011-09-20
Authors: Branduff McAllister; James F Gusella; G Bernhard Landwehrmeyer; Jong-Min Lee; Marcy E MacDonald; Michael Orth; Anne E Rosser; Nigel M Williams; Peter Holmans; Lesley Jones; Thomas H Massey Journal: Neurology Date: 2021-03-25 Impact factor: 11.800
Authors: Katalin Despotov; Dénes Zádori; Gábor Veres; Katalin Jakab; Gabriella Gárdián; Eszter Tóth; Tamás Zsigmond Kincses; László Vécsei; András Ajtay; Dániel Bereczki; Péter Klivényi Journal: BMC Neurol Date: 2021-02-18 Impact factor: 2.474